Difficulty: Medium
Average Score: 75%
Practice
Following is an irreversible inhibitor of GABA amino transferase
Correct answer
C
Rationale
In this Pharmacology CNS Drugs Quiz question, the correct answer is C) Vigabatrin. Vigabatrin is an irreversible inhibitor of GABA transaminase, an enzyme responsible for breaking down GABA (gamma-aminobutyric acid) in the brain. By inhibiting this enzyme, Vigabatrin increases the levels of GABA in the brain, leading to enhanced GABAergic neurotransmission and ultimately reducing neuronal excitability.
Option A) Pyrimidine is incorrect because it is a class of organic compounds and not a specific drug used as an irreversible inhibitor of GABA transaminase.
Option B) Lamotrigine is incorrect because it is an anticonvulsant medication that works by inhibiting voltage-gated sodium channels, not by inhibiting GABA transaminase.
Option D) Gabapentin is incorrect because it is a structural analog of GABA, but it does not directly inhibit GABA transaminase.
Understanding the mechanism of action of CNS drugs, such as GABAergic agents like Vigabatrin, is crucial for healthcare professionals in managing patients with epilepsy and other neurological disorders. By grasping how different drugs interact with specific targets in the brain, healthcare providers can make informed decisions about drug selection, dosing, and monitoring to optimize patient outcomes.
Option A) Pyrimidine is incorrect because it is a class of organic compounds and not a specific drug used as an irreversible inhibitor of GABA transaminase.
Option B) Lamotrigine is incorrect because it is an anticonvulsant medication that works by inhibiting voltage-gated sodium channels, not by inhibiting GABA transaminase.
Option D) Gabapentin is incorrect because it is a structural analog of GABA, but it does not directly inhibit GABA transaminase.
Understanding the mechanism of action of CNS drugs, such as GABAergic agents like Vigabatrin, is crucial for healthcare professionals in managing patients with epilepsy and other neurological disorders. By grasping how different drugs interact with specific targets in the brain, healthcare providers can make informed decisions about drug selection, dosing, and monitoring to optimize patient outcomes.